Saamya Biotech India Ltd IPO Message Board (Page 9)

now the broker call me he given me rate of 5-5.5,what you think i should sell it on rs 5/-

premium of rs 6to8 is wrong,it seems company made wrong qutation to oversubscibe the issue.co promoter is chitter

i have told my broker to sell it @ 5/ but ther were no buyer for samaya biotech

i have told my broker to sell it @ 5/ but ther were no buyer for samaya biotech

in this market false and chitter company gives good return

DONT APPLY

BY CHECKING ONLY GRAY MARKET PREMIUM DONT APPLY IT MAY BE A BIG TRAP READ IT

The promoters of the company Dr. Reddy and Mrs. Reddy, both are medicine qualified doctors, who are also promoters of Visu International Ltd. SEBI had imposed a penalty of Rs.50,000 on Visu for violations of SEBI regulations. The financial performance of this company has been nothing great. The paid-up equity of the company is Rs.35.33 crores, in which promoters’ stake is just 7%, with book-value of Rs.16.40, on 31-03-07. The share is ruling at Rs.16. EPS of the company for FY 07 was at Rs.4 which is discounted by 4 times. Really, poor discounting to the promoters and company.



Post issue, equity of the company at Rs.23.08 crores would be very high and may be difficult to service. Low promoters’ stake of 35% is also a dampener. The share is listing only on BSE.



Considering the size and financing pattern of the project and also track record of the promoters’, investment is not advised in this par issue. At Rs.10 also, when other companies are issuing its paper at premium, it is not attractive enough for the investors.

fixed price takes above 1 month for refund .good public issue premium 6.50 (all on mkt after 1 month)(high risk high return)
top buy :lml@14 target 20(by dec)(trade to trade),
gvfilm@9 target 14

I agree that the isuue is not fundamentally strong.
However the promoters are doctors though not experienced
in the relenant field. The stock market is good. Biotech industry has good future. The issue is at par. Unofficial premium is Rs6-7. So, guys - people who can take some risk
can apply for listing gains. Risk averse investors
can avoid.

Buy Sterling Holiday Resorts @ current level. First target 120 in short term.

IT IS WORTH INVESTING IN THIS ISSUE IT MAY GIVE HANDSOME LISTING GAINS LIKE INDOWIND.

this issue is for short term investors and for listing gains only

Is there any official way to check the subscription details ?

CAN EXPECT STRONG LISTING GAINS GUYS SUBSCRIBE

this is a VERY risky issue. I went through the prospectus today. Promoters are Andhra people who failed in their first biotech venture called Maanya Biotech.
They are now raising money for another of their quixotic ventures. They are getting technology from one foriegner and then selling to another foriegner (just one, mind you).
They only have a plot in Hyderabad biotech city - no electricity and no infrastructure.
Poor promoters with zero experience, just two products, technology being bought and prduct being sold only to one customer. This is a desaster waiting to happen.
I wonder why UTI securities is risking its reputation by being the lead manager.
This company is going to vanish just like so many others which came out in the height of the previous bull run - Midwest iron and steel (1996), DSQ and their like is getting another addition.
We as investors must defeat the designs these people have on our money, Please avoid this company - investing just because the issue is at per and may give a pop on listing should be avoided because ultimately some investors will get burnt in this quixotic venture

How to check subscription for Samya Boitech ? Any Info ?

@Ranjit,

Subscription details cant be got for Fixed price issues......

this is a super ipo come on invester do it

total oversubscribed .42 times at 5pm on 27 sep

I think Saamya Biotech (India) Ltd. (SBIL) IPO will give listing gain of about 60% and one should subscribe for it.

how many time has it been oversubscribed..............no details.......